Description
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer, unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).
Key stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | -34.74% | -51.85% |
| Operating margin | -31.06% | -74.88% |
| EBITD margin | - | -50.28% |
| Return on average assets | -12.71% | -13.59% |
| Return on average equity | -18.53% | -22.85% |
| Employees | 741 |
No comments:
Post a Comment